| Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer EE Parkes, SM Walker, LE Taggart, N McCabe, LA Knight, R Wilkinson, ... Journal of the National Cancer Institute 109 (1), djw199, 2017 | 408 | 2017 |
| Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application G Lightbody, V Haberland, F Browne, L Taggart, H Zheng, E Parkes, ... Briefings in bioinformatics 20 (5), 1795-1811, 2019 | 168 | 2019 |
| Metastasis and immune evasion from extracellular cGAMP hydrolysis J Li, MA Duran, N Dhanota, WK Chatila, SE Bettigole, J Kwon, RK Sriram, ... Cancer discovery 11 (5), 1212-1227, 2021 | 167 | 2021 |
| Development of immunotherapy combination strategies in cancer TA Yap, EE Parkes, W Peng, JT Moyers, MA Curran, HA Tawbi Cancer discovery 11 (6), 1368-1397, 2021 | 164 | 2021 |
| Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model Y Philippou, HT Sjoberg, E Murphy, S Alyacoubi, KI Jones, ... British journal of cancer 123 (7), 1089-1100, 2020 | 61 | 2020 |
| The tumor microenvironment and immune responses in prostate cancer patients JTW Kwon, RJ Bryant, EE Parkes Endocrine-Related Cancer 28 (8), T95-T107, 2021 | 52 | 2021 |
| Automated tumour recognition and digital pathology scoring unravels new role for PD-L1 in predicting good outcome in ER-/HER2+ breast cancer MP Humphries, S Hynes, V Bingham, D Cougot, J James, F Patel-Socha, ... Journal of Oncology 2018, 2018 | 52 | 2018 |
| Non-cell-autonomous cancer progression from chromosomal instability J Li, MJ Hubisz, EM Earlie, MA Duran, C Hong, AA Varela, E Lettera, ... Nature 620 (7976), 1080-1088, 2023 | 40 | 2023 |
| Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial P Sharma, WE Barlow, AK Godwin, EE Parkes, LA Knight, SM Walker, ... Journal of Clinical Oncology 37 (36), 3484, 2019 | 38 | 2019 |
| A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer NE Buckley, P Haddock, RDM Simoes, E Parkes, G Irwin, F Emmert-Streib, ... Oncotarget 7 (15), 19884, 2016 | 34 | 2016 |
| When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers MATM van Vugt, EE Parkes Trends in cancer 8 (3), 174-189, 2022 | 29 | 2022 |
| Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma RC Turkington, LA Knight, JK Blayney, M Secrier, R Douglas, EE Parkes, ... Gut 68 (11), 1918-1927, 2019 | 25 | 2019 |
| DNA repair deficiency in breast cancer: opportunities for immunotherapy E Gilmore, N McCabe, RD Kennedy, EE Parkes Journal of oncology 2019, 2019 | 25 | 2019 |
| Scientific progress is built on failure E Parkes Nature 10, 2019 | 24 | 2019 |
| The clinical and molecular significance associated with STING signaling in breast cancer EE Parkes, MP Humphries, E Gilmore, FA Sidi, V Bingham, SM Phyu, ... NPJ Breast Cancer 7 (1), 81, 2021 | 22 | 2021 |
| Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study RS McCain, DT McManus, S McQuaid, JA James, M Salto-Tellez, ... Cancer causes & control 31, 1-11, 2020 | 22 | 2020 |
| Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer EE Parkes, KI Savage, T Lioe, C Boyd, S Halliday, SM Walker, K Lowry, ... British journal of cancer 126 (2), 247-258, 2022 | 20 | 2022 |
| cGAS–STING signalling in cancer: striking a balance with chromosomal instability B Beernaert, EE Parkes Biochemical Society Transactions 51 (2), 539, 2023 | 13 | 2023 |
| Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021; 11: 1368–1397. doi: 10.1158/2159-8290 TA Yap, EE Parkes, W Peng, JT Moyers, MA Curran, HA Tawbi CD-20-1209.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 12 | |
| A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer CE Fletcher, L Deng, F Orafidiya, W Yuan, M Lorentzen, OW Cyran, ... Molecular Cancer 21 (1), 82, 2022 | 10 | 2022 |
